Please note a correction is necessary in the article, “Hepatorenal Syndrome: Do the Vasoconstrictors Work?” by Drs Wesley Leung and Florence Wong, which published in the September 2011 issue of Gastroenterology Clinics of North America (40:3, pp 581–598). Following are the corrected source lines for Figures 2 and 3:

Figure 2 a: From Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008;134:1360–8; with permission.

Figure 2 b: From Martín-Llahí M, Pépin MN, Guevara M, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008;134:1352–9; with permission.

Figure 3 : From Sharma P, Kumar A, Shrama BC et al. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol 2008;103:1689–97; with permission.